Medicus Pharma Advances Teverelix Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix in an underserved population representing ~$4 billion annual market opportunity

PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced the successful submission of a substantial modification application through the European Union Clinical Trials Information System (CTIS) supporting the planned Phase 2b study of Teverelix in advanced prostate cancer (APC).

The submission represents an important milestone in Medicus’ strategy to advance Teverelix toward registrational development focused on one of the largest unmet needs in prostate cancer treatment: patients with elevated cardiovascular risk requiring androgen deprivation therapy (ADT).

“Cardiovascular disease remains one of the most significant challenges facing men undergoing androgen deprivation therapy,” stated Dr. Raza Bokhari, Medicus’ Executive Chairman & CEO, “We believe Teverelix’s unique pharmacologic profile, including flare-free rapid testosterone suppression, profound follicle-stimulating hormone suppression and a long-acting depot formulation, may offer meaningful advantages for this patient population. This study is intended to generate the data necessary to support registrational planning and advance discussions with regulatory authorities in Europe and the United States.”

The planned Phase 2b study is designed to optimize dose selection and further characterize the pharmacokinetic, pharmacodynamic, efficacy and safety profile of Teverelix ahead of planned registrational development. Medicus has previously engaged extensively with the U.S. Food and Drug Administration regarding its APC development strategy, including future studies focused on patients with elevated cardiovascular risk.

Teverelix: Differentiated Mechanism with Cardiovascular Relevance

Teverelix is a long-acting GnRH antagonist designed to provide rapid, flare-free testosterone suppression together with profound follicle-stimulating hormone (FSH) suppression through a convenient depot formulation. The Company believes these characteristics may provide meaningful differentiation from traditional GnRH agonists and support evaluation in patients where cardiovascular outcomes are of particular importance.

Schreibe Deinen Kommentar